Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The microbiota of the gastrointestinal tract is an ecosystem comprising trillions of microbes—primarily bacteria (such as Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria) as well as archaea, fungi, protists, and viruses—living throughout the digestive system, with the highest density in the colon. It plays a fundamental role in host metabolism, immune function, protection against pathogens, and even influences neurological processes via the microbiota–gut–brain axis. Dysbiosis, or imbalance in this community, is linked to multiple diseases, making manipulation of the gut microbiota a major focus of emerging therapeutic strategies. However, it is not an individual molecular target, but a descriptor for a complex, interacting microbial consortium.
Competitive inhibition of pathogens; Production of bioactive metabolites (e.g., short-chain fatty acids, neurotransmitters); Enhanced mucosal immune tolerance; Modulation of local and systemic inflammation; Restoration of functional microbial communities (e.g., after dysbiosis)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microbiota of the gastrointestinal tract (gut microbiota).